These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 38143247)

  • 21. Anatomical barriers against SARS-CoV-2 neuroinvasion at vulnerable interfaces visualized in deceased COVID-19 patients.
    Khan M; Clijsters M; Choi S; Backaert W; Claerhout M; Couvreur F; Van Breda L; Bourgeois F; Speleman K; Klein S; Van Laethem J; Verstappen G; Dereli AS; Yoo SJ; Zhou H; Dan Do TN; Jochmans D; Laenen L; Debaveye Y; De Munter P; Gunst J; Jorissen M; Lagrou K; Meersseman P; Neyts J; Thal DR; Topsakal V; Vandenbriele C; Wauters J; Mombaerts P; Van Gerven L
    Neuron; 2022 Dec; 110(23):3919-3935.e6. PubMed ID: 36446381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regeneration Profiles of Olfactory Epithelium after SARS-CoV-2 Infection in Golden Syrian Hamsters.
    Urata S; Maruyama J; Kishimoto-Urata M; Sattler RA; Cook R; Lin N; Yamasoba T; Makishima T; Paessler S
    ACS Chem Neurosci; 2021 Feb; 12(4):589-595. PubMed ID: 33522795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptive Immune Responses and Immunity to SARS-CoV-2.
    Primorac D; Vrdoljak K; Brlek P; Pavelić E; Molnar V; Matišić V; Erceg Ivkošić I; Parčina M
    Front Immunol; 2022; 13():848582. PubMed ID: 35603211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oromucosal immunomodulation as clinical spectrum mitigating factor in SARS-CoV-2 infection.
    Rodríguez-Argente F; Alba-Domínguez M; Ortiz-Muñoz E; Ortega-González Á
    Scand J Immunol; 2021 Jan; 93(1):e12972. PubMed ID: 32892403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients.
    Yachou Y; El Idrissi A; Belapasov V; Ait Benali S
    Neurol Sci; 2020 Oct; 41(10):2657-2669. PubMed ID: 32725449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 induces inflammation and intracranial infection through the olfactory epithelium-olfactory bulb pathway in non-human primates.
    Shimizu S; Nakayama M; Nguyen CT; Ishigaki H; Kitagawa Y; Yasui F; Yagi Y; Kusayanagi T; Kohara M; Itoh Y; Tojima I; Kouzaki H; Shimizu T
    J Neuroimmunol; 2024 Feb; 387():578288. PubMed ID: 38237527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal mucosal immunity and COVID-19.
    Velikova T; Snegarova V; Kukov A; Batselova H; Mihova A; Nakov R
    World J Gastroenterol; 2021 Aug; 27(30):5047-5059. PubMed ID: 34497434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models.
    Butowt R; Meunier N; Bryche B; von Bartheld CS
    Acta Neuropathol; 2021 Jun; 141(6):809-822. PubMed ID: 33903954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress of cGAS-STING signaling in response to SARS-CoV-2 infection.
    Wu Y; Zhang M; Yuan C; Ma Z; Li W; Zhang Y; Su L; Xu J; Liu W
    Front Immunol; 2022; 13():1010911. PubMed ID: 36569852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mucosal Gene Expression in Response to SARS-CoV-2 Is Associated with Viral Load.
    Rajagopala SV; Strickland BA; Pakala SB; Kimura KS; Shilts MH; Rosas-Salazar C; Brown HM; Freeman MH; Wessinger BC; Gupta V; Phillips E; Mallal SA; Turner JH; Das SR
    J Virol; 2023 Feb; 97(2):e0147822. PubMed ID: 36656015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
    Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
    Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age.
    Bilinska K; Jakubowska P; Von Bartheld CS; Butowt R
    ACS Chem Neurosci; 2020 Jun; 11(11):1555-1562. PubMed ID: 32379417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmission and Protection against Reinfection in the Ferret Model with the SARS-CoV-2 USA-WA1/2020 Reference Isolate.
    Patel DR; Field CJ; Septer KM; Sim DG; Jones MJ; Heinly TA; Vanderford TH; McGraw EA; Sutton TC
    J Virol; 2021 Jun; 95(13):e0223220. PubMed ID: 33827954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-viral effects of COVID-19 in the olfactory system and their implications.
    Xydakis MS; Albers MW; Holbrook EH; Lyon DM; Shih RY; Frasnelli JA; Pagenstecher A; Kupke A; Enquist LW; Perlman S
    Lancet Neurol; 2021 Sep; 20(9):753-761. PubMed ID: 34339626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can the immunological system of the upper respiratory tract, improved by physical exercise, act as a first immunological barrier against SARS-CoV-2?
    Azócar-Gallardo J; Ojeda-Aravena A; Carrizo Largo J; Hernández-Mosqueira C
    Expert Rev Anti Infect Ther; 2022 Jul; 20(7):981-986. PubMed ID: 35412405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An update on host immunity correlates and prospects of re-infection in COVID-19.
    Negi N; Maurya SP; Singh R; Das BK
    Int Rev Immunol; 2022; 41(4):367-392. PubMed ID: 34961403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolution of nasal and olfactory infection characteristics of SARS-CoV-2 variants.
    Chen M; Pekosz A; Villano JS; Shen W; Zhou R; Kulaga H; Li Z; Smith A; Gurung A; Beck SE; Witwer KW; Mankowski JL; Ramanathan M; Rowan NR; Lane AP
    J Clin Invest; 2024 Mar; 134(8):. PubMed ID: 38483537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.